Ldl-C Lowering Efficacy of Evolocumab (Amg 145) Could Reduce Apheresis in Patients At High Risk for Cardiovascular Events in Germany
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.1528
https://www.valueinhealthjournal.com/article/S1098-3015(14)03458-5/fulltext
Title :
Ldl-C Lowering Efficacy of Evolocumab (Amg 145) Could Reduce Apheresis in Patients At High Risk for Cardiovascular Events in Germany
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)03458-5&doi=10.1016/j.jval.2014.08.1528
First page :
A504
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1007